Evidence map›Paper›PMID 39735552›Full record

Observational studyFrontiers in immunology2024

Frequency, characteristics, and immunological accompaniments of ataxia in anti-NMDAR antibody-associated encephalitis.

Sarah Jesse, Marie Riemann, Hauke Schneider, Marius Ringelstein, Nico Melzer, Niklas Vogel, Lena Kristina Pfeffer, Manuel A Friese, Kurt-Wolfram Sühs, Dominica Hudasch and 16 more

Abstract readObservational Study
In one paragraph

Observational study in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Sarah JesseDepartment of Neurology, University Hospital Ulm, Ulm, Germany.
Marie RiemannDepartment of Neurology, University Hospital Ulm, Ulm, Germany.
Hauke SchneiderDepartment of Neurology, Augsburg University, Augsburg, Germany.
Marius RingelsteinDepartment of Neurology, Medical Faculty, Heinrich Heine University of Düsseldorf, Düsseldorf, Germany.
Nico MelzerDepartment of Neurology, Medical Faculty, Heinrich Heine University of Düsseldorf, Düsseldorf, Germany.
Niklas VogelDepartment of Neurology, Medical Faculty, Heinrich Heine University of Düsseldorf, Düsseldorf, Germany.
Lena Kristina PfefferInstitute of Neuroimmunology and Multiple Sclerosis and Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Manuel A FrieseInstitute of Neuroimmunology and Multiple Sclerosis and Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Kurt-Wolfram SühsDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Dominica HudaschDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Philipp SchwenkenbecherDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Albrecht GüntherSection of Translational Neuroimmunology, Department of Neurology, Jena University Hospital, Jena, Germany.
Christian GeisSection of Translational Neuroimmunology, Department of Neurology, Jena University Hospital, Jena, Germany.
Jonathan WickelSection of Translational Neuroimmunology, Department of Neurology, Jena University Hospital, Jena, Germany.
Martin LesserDepartment of Neurology, Carl Gustav Carus University Dresden, Dresden, Germany.
Annika KatherDepartment of Neurology, Carl Gustav Carus University Dresden, Dresden, Germany.
Frank LeypoldtInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel/Lubeck, Germany.
Justina DargvainieneInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel/Lubeck, Germany.
Robert MarkewitzInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel/Lubeck, Germany.
Klaus-Peter WandingerInstitute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel/Lubeck, Germany.
Franziska S ThalerInstitute of Clinical Neuroimmunology, LMU University Hospital, LMU Munich, Munich, Germany.
Joseph KuchlingDepartment of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Katharina WurdackDepartment of Neurology and Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Lidia SabaterFundació de Recerca Biomèdica Clínic Barcelona-Institut d'Investigacions August Pi i Sunyer-Caixa Research Institute, Universitat de Barcelona, Barcelona, Spain.
Carsten FinkeBiomedical Center (BMC), Faculty of Medicine, LMU Munich, Munich, Germany.
Jan LewerenzDepartment of Neurology, University Hospital Ulm, Ulm, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Very rarely, adult NMDAR antibody-associated encephalitis (NMDAR-E) leads to persistent cerebellar atrophy and ataxia. Transient cerebellar ataxia is common in pediatric NMDAR-E. Immune-mediated cerebellar ataxia may be associated with myelin oligodendrocyte glycoprotein (MOG), aquaporin-4 (AQP-4), kelch-like family member 11 (KLHL11), and glutamate kainate receptor subunit 2 (GluK2) antibodies, all of which may co-occur in NMDAR-E. Here, we aimed to investigate the frequency, long-term outcome, and immunological concomitants of ataxia in NMDAR-E. Methods: In this observational study, patients with definite NMDAR-E with a follow-up of >12 months were recruited from the GENERATE registry. Cases with documented ataxia were analyzed in detail. Results: In 12 of 62 patients (19%), ataxia was documented. Bilateral cerebellar ataxia without additional focal CNS findings was found in four (one child and three adults); one of these was previously reported as a case with persistent cerebellar atrophy and ataxia. Two patients with bilateral cerebellar ataxia had additional focal neurological symptoms, optic neuritis and facial palsy. Two patients developed hemiataxia: one with diplopia suggesting brainstem dysfunction and the other probably resulting from cerebellar diaschisis due to contralateral status epilepticus. In all but the one developing cerebellar atrophy, cerebellar ataxia was transient and not associated with a worse long-term outcome. In all five patients with cerebellar ataxia tested, MOG, AQP-4, GluK2, and KLHL11 antibodies were negative. In two additional patients negative for both MOG and AQP-4 antibodies, ataxia was sensory and explained by cervical myelitis as part of multiple sclerosis (MS) manifesting temporal relation to NMDAR-E. One of the patients with bilateral ataxia with focal neurological deficits was also diagnosed with MS upon follow-up. Finally, in two patients, ataxia was explained by cerebral hypoxic damage following circulatory failure during an ICU stay with severe NMDAR-E. Discussion: Ataxia of different types is quite common in NMDAR-E. Cerebellar ataxia in NMDAR-E is mostly transient. NMDAR-E followed by persistent ataxia and cerebellar atrophy is very rare. Cerebellar ataxia in NMDAR-E may not be explained by concomitant KLHL11, MOG, AQP-4, or GluK2 autoimmunity. Of note, ataxia in NMDAR-E may result from treatment complications and, most interestingly, from MS manifesting in temporal association with NMDAR-E.

Indexed as

Anti-N-Methyl-D-Aspartate Receptor EncephalitisAutoantibodiesAdolescentAdultAtaxiaCerebellar AtaxiaChildChild, PreschoolFemaleHumansMaleMiddle AgedMyelin-Oligodendrocyte GlycoproteinYoung AdultAutoantibodiesMyelin-Oligodendrocyte Glycoproteinaquaporin-4 antibodyataxiacerebellumMOG antibodymultiple sclerosisNMDAR-encephalitisoutcome

Identifiers

PMID39735552
PMCPMC11681429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.